FDA approves Merck's Idvynso, a once-daily two-drug HIV-1 tablet for virologically suppressed adults in the US. This simplified regimen improves treatment adherence and reduces daily pill burden for people living with HIV.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
FDA approves once-daily Idvynso tablet for treating HIV
Two-Drug Single Tablet Medication formulation
Once Daily Dosing frequency
Doravirine/Islatravir Drug combination
Virologically Suppressed Adults target population
From Multiple To 1 Tablet daily medication reduction